|
Improved bioavailability with Megace ES For your AIDS patients who are experiencing unintended weight loss, specify Megace ES for its differences over original formula Megace®.*
• Original formula Megace had 83% lower bioavailability (Cmax) in unfed subjects vs. Megace ES†1 • There was comparable bioavailability between Megace ES and Megace in fed subjects1
*Megestrol acetate oral suspension. †Clinical significance unknown. Megace ES has improved absorption over original formula Megace in people who have not eaten (the unfed state). For people who have eaten (fed condition), Megace ES and original formula Megace have similar absorption into the body. The fed condition is achieved by subjects eating a high-calorie (800-1000 calories) and high-fat (approximately 50% of total calories) meal.16
|
Indication
Megace ES (megestrol acetate) is a concentrated suspension indicated for the treatment of anorexia (loss of appetite),
cachexia (severe malnutrition), or an unexplained, significant weight loss in people with a diagnosis of AIDS.1
Megace ES is available by Prescription Only. For full Prescribing Information, click here.
*Adverse events greater than placebo derived from the comprehensive adverse events table (≥5%) in Megace ES and megestrol acetate oral suspension prescribing information.
NanoCrystal® is a registered trade mark of Elan Pharma International Limited, Ireland.